291 related articles for article (PubMed ID: 11507208)
1. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
[TBL] [Abstract][Full Text] [Related]
2. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
[TBL] [Abstract][Full Text] [Related]
3. Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation.
Rusconi S; La Seta-Catamancio S; Kurtagic S; Galazzi M; Arienti D; Trabattoni D; Wilken J; Thompson DA; Offord RE; Galli M; Clerici M
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):861-7. PubMed ID: 10408722
[TBL] [Abstract][Full Text] [Related]
4. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
[TBL] [Abstract][Full Text] [Related]
5. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
[TBL] [Abstract][Full Text] [Related]
6. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
[TBL] [Abstract][Full Text] [Related]
7. Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.
Jansson M; Backström E; Björndal A; Holmberg V; Rossi P; Fenyö EM; Popovic M; Albert J; Wigzell H
J Hum Virol; 1999; 2(6):325-38. PubMed ID: 10774549
[TBL] [Abstract][Full Text] [Related]
8. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
9. Endocytosis and recycling of the HIV coreceptor CCR5.
Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CD3/CD28-mediated activation of the MEK/ERK signaling pathway represses replication of X4 but not R5 human immunodeficiency virus type 1 in peripheral blood CD4(+) T lymphocytes.
Popik W; Pitha PM
J Virol; 2000 Mar; 74(6):2558-66. PubMed ID: 10684270
[TBL] [Abstract][Full Text] [Related]
11. The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
Alfano M; Schmidtmayerova H; Amella CA; Pushkarsky T; Bukrinsky M
J Exp Med; 1999 Sep; 190(5):597-605. PubMed ID: 10477545
[TBL] [Abstract][Full Text] [Related]
12. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.
Rusconi S; La Seta Catamancio S; Citterio P; Bulgheroni E; Croce F; Herrmann SH; Offord RE; Galli M; Hirsch MS
J Virol; 2000 Oct; 74(19):9328-32. PubMed ID: 10982382
[TBL] [Abstract][Full Text] [Related]
13. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.
Zhang Y; Lou B; Lal RB; Gettie A; Marx PA; Moore JP
J Virol; 2000 Aug; 74(15):6893-910. PubMed ID: 10888629
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of R5X4 dualtropic HIV-1 primary isolates by single chemokine co-receptor ligands.
Ghezzi S; Menzo S; Brambilla A; Bordignon PP; Lorini AL; Clementi M; Poli G; Vicenzi E
Virology; 2001 Feb; 280(2):253-61. PubMed ID: 11162839
[TBL] [Abstract][Full Text] [Related]
15. Identification of an unique CXCR4 epitope whose ligation inhibits infection by both CXCR4 and CCR5 tropic human immunodeficiency type-I viruses.
Adachi T; Tanaka R; Kodama A; Saito M; Takahashi Y; Ansari AA; Tanaka Y
Retrovirology; 2011 Oct; 8():84. PubMed ID: 22018245
[TBL] [Abstract][Full Text] [Related]
16. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.
Trkola A; Ketas TJ; Nagashima KA; Zhao L; Cilliers T; Morris L; Moore JP; Maddon PJ; Olson WC
J Virol; 2001 Jan; 75(2):579-88. PubMed ID: 11134270
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
[TBL] [Abstract][Full Text] [Related]
18. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.
Simmons G; Clapham PR; Picard L; Offord RE; Rosenkilde MM; Schwartz TW; Buser R; Wells TN; Proudfoot AE
Science; 1997 Apr; 276(5310):276-9. PubMed ID: 9092481
[TBL] [Abstract][Full Text] [Related]
19. Galphai protein-dependant extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription.
Mettling C; Desmetz C; Fiser AL; Réant B; Corbeau P; Lin YL
AIDS; 2008 Aug; 22(13):1569-76. PubMed ID: 18670215
[TBL] [Abstract][Full Text] [Related]
20. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
Baba M; Nishimura O; Kanzaki N; Okamoto M; Sawada H; Iizawa Y; Shiraishi M; Aramaki Y; Okonogi K; Ogawa Y; Meguro K; Fujino M
Proc Natl Acad Sci U S A; 1999 May; 96(10):5698-703. PubMed ID: 10318947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
